Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?

被引:17
作者
Favaloro, Emmanuel J. [1 ]
Plebani, Mario [2 ]
Lippi, Giuseppe [3 ,4 ]
机构
[1] Westmead Hosp, WSAHS, Inst Clin Pathol & Med Res ICPMR, Dept Haematol, Westmead, NSW 2145, Australia
[2] Univ Hosp, Dept Lab Med, Padua, Italy
[3] Acad Hosp Parma, Dept Pathol, Parma, Italy
[4] Acad Hosp Parma, Lab Med, Clin Chem & Hematol Lab, Parma, Italy
关键词
accreditation; external quality assurance; in vitro diagnostics; IVDs; professional status; regulation; QUALITY-ASSURANCE; EMERGING TECHNOLOGIES; STANDARDIZATION; HEMOSTASIS; ANTIBODY; THROMBOSIS; PATHOLOGY; PROGRAM;
D O I
10.1515/CCLM.2011.690
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A revised framework for the regulation of in vitro diagnostic devices (IVDs) came into force in Australia on July 1, 2010 that aims to 'ensure that public and personal health are adequately protected', but which instead may lead to adverse outcomes in clinical diagnosis and management. The regulatory process aims to regulate all IVDs, including those used by clinical diagnostic laboratories, which are already subject to scrutiny as part of the current laboratory accreditation process. The IVD regulatory process initiated in Australia is similar to that used in Canada, but different to that currently operating in the USA and Europe. However, it is feasible that other countries will in time adopt a similar regulatory framework, given that many countries are involved in the development process. In this opinion paper, the regulatory process for IVDs across several geographies are outlined, as are some benefits and weaknesses of the new regulatory process now applied to Australia, as potentially planned for other regions of the world.
引用
收藏
页码:1965 / 1973
页数:9
相关论文
共 29 条
[1]  
[Anonymous], COST REC IMP STAT 20
[2]  
[Anonymous], OV NEW REG FRAM VITR
[3]  
[Anonymous], IVD ROADM
[4]  
[Anonymous], FEE STRUCT IVD APPL
[5]  
[Anonymous], PROCEDURES VALIDATIO
[6]  
Bonar R, 2010, BIOCHEM MEDICA, V20, P184
[7]  
Cohen Paul, 2010, Australian Journal of Medical Science, V31, P9
[8]   The new European directive on in vitro diagnostics [J].
Dati, F .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (10) :1289-1298
[9]   A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing [J].
Favaloro, EJ ;
Wong, RCW ;
Silvestrini, R ;
McEvoy, R ;
Jovanovich, S ;
Roberts-Thomson, P .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (01) :73-84
[10]   An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult [J].
Favaloro, Emmanuel J. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (08) :727-744